Alzamend Neuro Inc. (ALZN)
NASDAQ: ALZN
· Real-Time Price · USD
2.35
-0.01 (-0.42%)
At close: Sep 26, 2025, 10:57 AM
-0.42% (1D)
| Bid | 2.35 |
| Market Cap | 7.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.24M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -2 |
| Forward PE | -0.48 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.36 |
| Volume | 28,653 |
| Avg. Volume (20D) | 171,946.4 |
| Open | 2.36 |
| Previous Close | 2.36 |
| Day's Range | 2.35 - 2.37 |
| 52-Week Range | 2.06 - 17.10 |
| Beta | -0.30 |
| Ex-Dividend Date | n/a |
About ALZN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALZN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-29.6%
Alzamend Neuro shares are trading lower. The stock...
Unlock content with
Pro Subscription
4 months ago
+63.86%
Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.
